Ocular Therapeutix Files 2024 Annual Report
Ticker: OCUL · Form: 10-K · Filed: Mar 3, 2025 · CIK: 1393434
| Field | Detail |
|---|---|
| Company | Ocular Therapeutix, Inc (OCUL) |
| Form Type | 10-K |
| Filed Date | Mar 3, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: annual-report, pharmaceuticals, financials
Related Tickers: OCUT
TL;DR
OCULAR THERAPEUTIX (OCUT) FILED ITS 2024 10-K. CHECK FINANCIALS & RISKS.
AI Summary
Ocular Therapeutix, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, headquartered in Bedford, MA, operates in the pharmaceutical preparations sector. This filing provides a comprehensive overview of its financial performance, business operations, and risk factors for the period.
Why It Matters
This 10-K filing is crucial for investors and stakeholders to understand Ocular Therapeutix's financial health, strategic direction, and potential risks as of December 31, 2024.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Ocular Therapeutix faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- OCULAR THERAPEUTIX, INC (company) — Filer
- 20241231 (date) — Fiscal Year End
- 20250303 (date) — Filing Date
- Bedford, MA (location) — Company Headquarters
- 2834 (industry_code) — Standard Industrial Classification
FAQ
What was Ocular Therapeutix's total revenue for the fiscal year ending December 31, 2024?
The provided text does not contain specific revenue figures for the fiscal year ending December 31, 2024.
What are the primary products or drug candidates mentioned in the filing?
The provided text does not detail specific products or drug candidates.
What is the company's reported net income or loss for the fiscal year 2024?
The provided text does not include net income or loss figures.
Are there any significant acquisitions or divestitures mentioned in the 2024 10-K?
The provided text does not mention any acquisitions or divestitures.
What is the company's cash and cash equivalents balance as of December 31, 2024?
The provided text does not specify the cash and cash equivalents balance.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 3, 2025 regarding OCULAR THERAPEUTIX, INC (OCUL).